This whitepaper highlights how reliance on overall survival (OS) in oncology trials, though robust, delays access to new treatments and overlooks patient priorities like quality of life, progression-free survival, and event-free survival. Alternative oncology-relevant endpoints (OREs), including biomarkers and patient-reported outcomes, offer earlier and more meaningful measures but face barriers: uncertainty about their validity, misalignment across stakeholders, and inconsistent data collection. The paper recommends cross-stakeholder alignment, standardization, and evidence generation to build portfolios of fit-for-purpose endpoints by cancer type and stage.

Join for free to read